Barchart on MSN
Intellia Therapeutics stock is down nearly 95% from its record highs but Cathie Wood keeps buying
Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes ...
Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its ...
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Fintel reports that on March 4, 2026, Jones Trading upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Hold to Buy. As of February 25, 2026, the average one-year price target for ...
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results